BioXcel Therapeutics, Inc.
BTAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $98 | $120 | $168 | $366 |
| % Growth | -18.3% | -28.6% | -54.1% | – |
| Cost of Goods Sold | $86 | $107 | $14 | $832 |
| Gross Profit | $12 | $13 | $154 | -$466 |
| % Margin | 12.2% | 10.8% | 91.7% | -127.3% |
| R&D Expenses | $8,560 | $10,256 | $4,554 | $5,901 |
| G&A Expenses | $0 | $5,571 | $5,699 | $3,612 |
| SG&A Expenses | $5,380 | $5,609 | $5,699 | $4,094 |
| Sales & Mktg Exp. | $0 | $38 | $0 | $482 |
| Other Operating Expenses | $0 | $0 | $0 | $32 |
| Operating Expenses | $13,940 | $15,865 | $10,253 | $10,027 |
| Operating Income | -$13,928 | -$15,852 | -$10,099 | -$10,493 |
| % Margin | -14,212.2% | -13,210% | -6,011.3% | -2,866.9% |
| Other Income/Exp. Net | -$16,983 | -$3,335 | $2,845 | -$366 |
| Pre-Tax Income | -$30,911 | -$19,187 | -$7,254 | -$10,859 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30,911 | -$19,187 | -$7,254 | -$10,859 |
| % Margin | -31,541.8% | -15,989.2% | -4,317.9% | -2,966.9% |
| EPS | -2.18 | -2.45 | -1.5 | -3.57 |
| % Growth | 11% | -63.3% | 58% | – |
| EPS Diluted | -2.18 | -2.45 | -1.5 | -3.57 |
| Weighted Avg Shares Out | 14,196 | 7,843 | 4,834 | 3,039 |
| Weighted Avg Shares Out Dil | 14,196 | 7,843 | 4,834 | 3,039 |
| Supplemental Information | – | – | – | – |
| Interest Income | $236 | $230 | $1,053 | $368 |
| Interest Expense | $4,373 | $4,222 | $0 | $4,032 |
| Depreciation & Amortization | $75 | $75 | $76 | $77 |
| EBITDA | -$26,463 | -$14,890 | -$3,185 | -$6,750 |
| % Margin | -27,003.1% | -12,408.3% | -1,895.8% | -1,844.3% |